Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
|Slideshows|October 30, 2017
9 Natural Supplements for Cognitive Impairment
Which vitamins and supplements have shown promise in treating dementia and preventing cognitive decline?
Advertisement
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162
2
Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study
3
Recapping the 2026 STARS Conference and the Push for Interdisciplinary Stuttering Care: Gerald Maguire, MD
4
Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development
5